Pierre De Marini1, Roberto Luigi Cazzato1, Julien Garnon1, Thibault Tricard2, Guillaume Koch1, Georgia Tsoumakidou1,3, Nitin Ramamurthy4, Hervé Lang2, Afshin Gangi1. 1. 1 Department of Interventional Radiology, University Hospital of Strasbourg, 1 Place de l'Hôpital , Strasbourg , France. 2. 2 Department of Urology, University Hospital of Strasbourg, 1 Place de l'Hôpital , Strasbourg , France. 3. 3 Department of Interventional Radiology, University Hospital of Lausanne , Switzerland. 4. 4 Department of Radiology, Norfolk and Norwich University Hospital , Norwich , UK.
Abstract
OBJECTIVE: To assess the safety and oncological efficacy of percutaneous MR-guided whole-gland prostate cancer (PCa) cryoablation (CA). METHODS AND MATERIALS: Between July 2009 and January 2018, 30 patients (mean age 72.9 ± 5.13 years) with histologically proven, organ-confined (≤ T2cN0M0), predominantly low/intermediate-risk PCa (median Gleason score 7; mean prostate specific antigen 6.05 ± 3.74 ng ml-1 ) underwent MR-guided whole-gland CA. Patients were selected on the basis of prior pelvic radiotherapy (n = 16; 12 for previous PCa), or contra indication/refusal of surgery or radiotherapy. Complications, local progression-free survival (LPFS) and overall survival (OS) were retrospectively investigated. RESULTS: Eighteen [60%] patients reported procedure-related complications: 5/18 [28%] needed surgical/interventional treatments and 13 [72%] conservative or pharmacological treatment. Eleven [73%] complications were noted in the first 15 patients and 7 [47%] in the last 15 patients (p = 0.26). Mean nadir prostate specific antigen was 0.24 ± 1.5 ng ml-1 (mean follow-up 3.8 years; range: 2 - 2915 days). Seven [23%] patients developed histologically proven local progression (mean time to recurrence 775 days, range: 172 - 2014). Mean clinical follow-up was 3.8 years (range 1-2915 days). LPFS was 92.0, 75.7 and 69.4 % at 1-, 3- and 5 year follow-up, respectively. For patients in salvage treatment, LPFS was 100%, 75%, and 75% at 1-, 3- and 5 year follow-up. OS was 100%, 94.4 and 88.5 % at 1-, 3- and 5 year follow-up respectively, with no patients dying from PCa. CONCLUSION: Whole-gland PCa CA offers good oncological efficacy, particularly in post-radiotherapy cases. Although the complication rate is significant, the majority is minor and is managed with conservative or pharmacologic management. ADVANCES IN KNOWLEDGE: MRI-guided whole-gland prostate cancer cryoablation offers good oncological efficacy, particularly in post-radiotherapy cases with a contained complication rate.
OBJECTIVE: To assess the safety and oncological efficacy of percutaneous MR-guided whole-gland prostate cancer (PCa) cryoablation (CA). METHODS AND MATERIALS: Between July 2009 and January 2018, 30 patients (mean age 72.9 ± 5.13 years) with histologically proven, organ-confined (≤ T2cN0M0), predominantly low/intermediate-risk PCa (median Gleason score 7; mean prostate specific antigen 6.05 ± 3.74 ng ml-1 ) underwent MR-guided whole-gland CA. Patients were selected on the basis of prior pelvic radiotherapy (n = 16; 12 for previous PCa), or contra indication/refusal of surgery or radiotherapy. Complications, local progression-free survival (LPFS) and overall survival (OS) were retrospectively investigated. RESULTS: Eighteen [60%] patients reported procedure-related complications: 5/18 [28%] needed surgical/interventional treatments and 13 [72%] conservative or pharmacological treatment. Eleven [73%] complications were noted in the first 15 patients and 7 [47%] in the last 15 patients (p = 0.26). Mean nadir prostate specific antigen was 0.24 ± 1.5 ng ml-1 (mean follow-up 3.8 years; range: 2 - 2915 days). Seven [23%] patients developed histologically proven local progression (mean time to recurrence 775 days, range: 172 - 2014). Mean clinical follow-up was 3.8 years (range 1-2915 days). LPFS was 92.0, 75.7 and 69.4 % at 1-, 3- and 5 year follow-up, respectively. For patients in salvage treatment, LPFS was 100%, 75%, and 75% at 1-, 3- and 5 year follow-up. OS was 100%, 94.4 and 88.5 % at 1-, 3- and 5 year follow-up respectively, with no patients dying from PCa. CONCLUSION: Whole-gland PCa CA offers good oncological efficacy, particularly in post-radiotherapy cases. Although the complication rate is significant, the majority is minor and is managed with conservative or pharmacologic management. ADVANCES IN KNOWLEDGE: MRI-guided whole-gland prostate cancer cryoablation offers good oncological efficacy, particularly in post-radiotherapy cases with a contained complication rate.
Authors: Kristin A Kinsman; Mariah L White; Lance A Mynderse; Akira Kawashima; Karen Rampton; Krzysztof R Gorny; Thomas D Atwell; Joel P Felmlee; Matthew R Callstrom; David A Woodrum Journal: Cardiovasc Intervent Radiol Date: 2017-10-17 Impact factor: 2.740
Authors: Melissa H Mendez; Niccolo Maria Passoni; Julio Pow-Sang; J Stephen Jones; Thomas J Polascik Journal: J Endourol Date: 2015-07-13 Impact factor: 2.942
Authors: William C Huang; Kentaro Kuroiwa; Angel M Serio; Fernando J Bianco; Samson W Fine; Bobby Shayegan; Peter T Scardino; James A Eastham Journal: J Urol Date: 2007-04 Impact factor: 7.450
Authors: Michael Kongnyuy; Courtney J Berg; Kaitlin E Kosinski; David J Habibian; Jeffrey T Schiff; Anthony T Corcoran; Aaron E Katz Journal: Int J Hyperthermia Date: 2017-03-29 Impact factor: 3.914
Authors: Bryan J Donnelly; John C Saliken; Penelope M A Brasher; Scott D Ernst; John C Rewcastle; Harold Lau; John Robinson; Kiril Trpkov Journal: Cancer Date: 2010-01-15 Impact factor: 6.860
Authors: John W Robinson; Bryan J Donnelly; Jodi E Siever; John C Saliken; Scott D Ernst; John C Rewcastle; Kiril Trpkov; Harold Lau; Cheryl Scott; Bejoy Thomas Journal: Cancer Date: 2009-10-15 Impact factor: 6.860
Authors: Massimo Valerio; Hashim U Ahmed; Mark Emberton; Nathan Lawrentschuk; Massimo Lazzeri; Rodolfo Montironi; Paul L Nguyen; John Trachtenberg; Thomas J Polascik Journal: Eur Urol Date: 2013-06-06 Impact factor: 20.096